How Do Bydureon BCise and the Original Bydureon Pen Differ?
Bydureon BCise and the original Bydureon (single-dose pen or tray) both deliver exenatide extended-release, a GLP-1 agonist for type 2 diabetes, but BCise simplifies administration. The original Bydureon pen required mixing powder and liquid with a syringe, while BCise uses a pre-mixed auto-injector.[1]
What's Easier About the BCise Needle and Injection?
BCise has a thinner 31-gauge needle (vs. 23-gauge on the original), reducing injection pain. It eliminates the 2-minute post-injection wait time of the original, which was needed for suspension settling. Users press a button for a fully automatic injection into the abdomen, thigh, or upper arm weekly.[1][2]
Why Did They Replace the Original Pen?
AstraZeneca discontinued the original Bydureon pen in 2018 due to manufacturing issues and lower demand. BCise, approved by the FDA in 2017, offers similar efficacy (HbA1c reduction of 1.5-1.6%) and safety but with higher patient preference in studies—89% favored BCise for ease.[1][3]
Do They Have the Same Dosing and Side Effects?
Both start at 2 mg weekly after possible 4-week titration, with identical side effects like nausea (most common, often mild), injection-site reactions, and thyroid tumor risk warnings. No difference in blood sugar control or weight loss (about 4 lbs average).[1][2]
Cost and Availability Now?
BCise costs $900-$1,000 monthly without insurance, similar to the original. It's the only Bydureon form available in the U.S., covered by most plans with copays under $50 via savings cards. Generic exenatide extended-release isn't approved yet.[1][4]
[1]: FDA Label for Bydureon BCise
[2]: AstraZeneca Prescribing Information
[3]: DAPA-CKD Study and Patient Preference Data
[4]: DrugPatentWatch.com - Bydureon Patents and Pricing